NNC0519-0130 vs VK2735

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Obesity

Shared mechanism: GLP-1/GIP receptor (dual) · full Obesity pipeline

NNC0519-0130

Developed by Novo Nordisk

Phase 2 in Obesitypeptide
Partial signal

NCT06326060 · Phase 2 · completed

The study was randomized and quadruple-blind, included placebo and active-comparator arms, and enrolled 354 participants; its primary endpoint was the clinical measure of relative body-weight change. Because the registry does not report whether this endpoint was met, the findings cannot currently support the highest evidence grade.

No aligned efficacy figure on record for this race.

VK2735

Developed by Viking Therapeutics

Phase 3 in Obesitypeptide
Reliable signal

NCT06828055 · Phase 2 · completed

This randomized, triple-blind, placebo-controlled Phase 2 trial (n=280) in adults with obesity found that oral VK2735 produced significantly greater weight loss than placebo at 13 weeks, up to 12.2% versus 1.3% (placebo-adjusted 10.9%, p<0.0001).

Caveat: this result is taken from a company announcement or a news report of one, not from the trial registry or a peer-reviewed publication. Treat the figures as the sponsor's own statement, not as independently verified evidence.

Next expected readout: May 2027 · NCT07838740 (registry estimate)

Reported efficacy

Percent (relative) change from baseline in body weight after 13 weeks of treatment: Primary endpoint (mean % body weight change from baseline at 13 weeks): up to -12.2% with oral VK2735 vs -1.3% placebo; placebo-adjusted -10.9%, p<0.0001 (met)

Result source: NCT06828055

Results for Obesity

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointNNC0519-0130VK2735
Body weight, % change—Not reported—Trial running · NCT07104500
Weight loss of 5% or more—Not reported—Trial running · NCT07104500
Weight loss of 10% or more—Not reported—Trial running · NCT07104500
Waist circumference, change (cm)—Not reported—Trial running · NCT07104500

Body weight, % change

NNC0519-0130
—Not reported
VK2735
—Trial running · NCT07104500

Weight loss of 5% or more

NNC0519-0130
—Not reported
VK2735
—Trial running · NCT07104500

Weight loss of 10% or more

NNC0519-0130
—Not reported
VK2735
—Trial running · NCT07104500

Waist circumference, change (cm)

NNC0519-0130
—Not reported
VK2735
—Trial running · NCT07104500
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

NNC0519-0130: no structured comparison results are available for Obesity.

Reviewed results are available, but are not yet structured for this comparison. These sourced summaries are shown separately from the aligned rows.

VK2735
Primary endpoint (mean % body weight change from baseline at 13 weeks): up to -12.2% with oral VK2735 vs -1.3% placebo; placebo-adjusted -10.9%, p<0.0001 NCT06828055 · Phase 2 · design grade: strong · publication or press release

Type 2 Diabetes

Shared mechanism: GLP-1/GIP receptor (dual) · full Type 2 Diabetes pipeline

NNC0519-0130

Developed by Novo Nordisk

Phase 2 in Type 2 Diabetespeptide
Weak signal

NCT05363774 · Phase 1 · completed

This was a randomized, blinded, placebo-controlled study, a genuine controlled design, but it measured only safety and drug levels rather than a clinical efficacy outcome, and results have not been posted yet, so the evidence reflects the design only. Its registered primary outcome on ClinicalTrials.gov is "Number of treatment emergent adverse events (TEAE) in single ascending dose (SAD) part" (with 3 other safety or dose-finding measures). Its registered primary outcomes are safety, tolerability or dose-finding measures only, so the evidence grade is capped at weak.

No aligned efficacy figure on record for this race.

VK2735

Developed by Viking Therapeutics

Phase 3 in Type 2 Diabetespeptide
not yet graded

No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.

Next expected readout: July 2027 · NCT07104383 (registry estimate)

No aligned efficacy figure on record for this race.

Results for Type 2 Diabetes

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointNNC0519-0130VK2735
HbA1c, change—Not reported—Trial running · NCT07104383
Body weight, change (kg)—Not reported—Trial running · NCT07104383
HbA1c below 7%—Not reported—Trial running · NCT07104383
Fasting plasma glucose, change—Not reported—Trial running · NCT07104383
3-point MACE (% with event)—Not reported—Trial running · NCT07104383

HbA1c, change

NNC0519-0130
—Not reported
VK2735
—Trial running · NCT07104383

Body weight, change (kg)

NNC0519-0130
—Not reported
VK2735
—Trial running · NCT07104383

HbA1c below 7%

NNC0519-0130
—Not reported
VK2735
—Trial running · NCT07104383

Fasting plasma glucose, change

NNC0519-0130
—Not reported
VK2735
—Trial running · NCT07104383

3-point MACE (% with event)

NNC0519-0130
—Not reported
VK2735
—Trial running · NCT07104383
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

NNC0519-0130: no structured comparison results are available for Type 2 Diabetes.

VK2735: no structured comparison results are available for Type 2 Diabetes.

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: NNC0519-0130's landscape · VK2735's landscape